Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2422082122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Marco C Miotto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cellular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Allopurinol, Xanthine, Muscle Weakness. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI), NINDS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Ryanodine receptors (RyRs) are intracellular Ca 2+ channels essential for muscle contraction. Caffeine, a xanthine derivative, has been known for decades to increase muscle contraction and enhance activation of RyRs by increasing the sensitivity to Ca 2+ . We previously showed that xanthine, the only physiologically relevant xanthine derivative, also binds to and activates RyR2. Most xanthine derivatives and analogs are safe and widely prescribed, with the most popular being the xanthine oxidoreductase inhibitor allopurinol (~15M yearly prescriptions in USA). We propose that xanthine derivatives and analogs that enhance RyRs activity could be used for lead optimization and eventually for the treatment of the diseases that exhibit decreased muscle contraction and reduced RyRs activity, such as RyR1-related diseases, sarcopenia, and heart failure. Here, we show by cryo-EM that xanthine derivatives, analogs, and other related compounds bind to the xanthine/caffeine binding site and activate RyR1, and identify 4-oxopyrimidine as the minimal motif necessary for such interaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Cellular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.
- Clyde and Helen Wu Center for Molecular Cardiology, Columbia University Medical Center, New York, NY 10032.
ORCID-Profile: Marco C Miotto, Steven Reiken, Yang Liu, Gunnar Weninger, Andrew R Marks
Förderung
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- NINDS NIH HHS
- NHLBI NIH HHS
- NIGMS NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Miotto, M. C., Luna-Figueroa, E., Tchagou, C., Bahlouli, L., Reiken, S., Dridi, H., Liu, Y., Weninger, G., & Marks, A. R. (2025). Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2422082122
Vancouver
Miotto MC, Luna-Figueroa E, Tchagou C, Bahlouli L, Reiken S, Dridi H, et al. Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2422082122
BibTeX
@article{Miotto2025,
author = {Miotto, Marco C and Luna-Figueroa, Estefania and Tchagou, Carl and Bahlouli, Laith and Reiken, Steven and Dridi, Haikel and Liu, Yang and Weninger, Gunnar and Marks, Andrew R},
title = {Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2422082122}
}
EUVIMED